Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
186.02B
Market cap186.02B
Price-Earnings ratio
10.07
Price-Earnings ratio10.07
Dividend yield
2.86%
Dividend yield2.86%
Average volume
12.59M
Average volume12.59M
High today
$42.76
High today$42.76
Low today
$41.22
Low today$41.22
Open price
$42.22
Open price$42.22
Volume
13.30M
Volume13.30M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Nasdaq 3h
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

Key Points Zealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients. That's g...

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
CNBC 5h
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Key Points Novo Nordisk and Eli Lilly are introducing GLP-1 pills for obesity, and that competition was on display this weekend at the American Diabetes Associa...

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
TipRanks 5h
Novo Nordisk Advances DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.8%

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

54%

of 37 ratings
Buy
37.8%
Hold
54.1%
Sell
8.1%

More NVO News

Benzinga 6h
Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs

The once-weekly therapy combines a novel amylin analog with a GLP-1 receptor agonist. Across all three studies, CagriSema met the primary endpoint of reducing H...

Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs
TipRanks 9h
Novo Nordisk Stock Drops despite Obesity Updates as Eli Lilly Takes All the Shine

Investors are cheering drugmaker Eli Lilly (LLY), with its shares up about 5% in Monday’s pre-market session, while archrival Novo Nordisk (NVO) dropped about 2...

Barron's 9h
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Biotech and Pharma Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. In this article LLY MU NVO Eli Lilly stock is up 47% ove...

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.
Benzinga 10h
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game'

"We have to be obsessed with what our patients want," Doustdar said Sunday in an interview with Bloomberg at the American Diabetes Association conference in New...

Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game'
The Wall Street Journal 13h
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch

Wegovy weight loss pills on a production line. The pill is now also launched in the United Arab Emirates. Novo Nordisk Novo Nordisk NOVO.B 4.43 %increase; gree...

Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch
MarketWatch 20h
The Wegovy pill is still dominating the GLP-1 pill market

At least 3 million prescriptions of the Wegovy pill have been filled for Americans since early January. It’s the latest sign of the unrelenting demand for weigh...

The Wegovy pill is still dominating the GLP-1 pill market
TipRanks 21h
Novo Nordisk announces Reimagine 1-3 trials each met primary endpoint

Phase 3 results from Novo Nordisk’s (NVO) Reimagine 1-3 trials were presented, showing significant reduction in HbA1c and weight in adults with type 2 diabetes....

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.